Rain Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019
Cash & Equivalents	61.96	24.78	58.86	5.79
Short-Term Investments	68.5	115.44	0	0
Cash & Cash Equivalents	130.45	140.22	58.86	5.79
Cash Growth	-6.96%	138.21%	915.93%	-
Other Current Assets	3.17	5.93	0.66	0.48
Total Current Assets	133.63	146.15	59.53	6.27
Property, Plant & Equipment	0.35	0.55	0.55	0.69
Other Long-Term Assets	1.2	0.44	1.01	0.43
Total Long-Term Assets	1.55	0.99	1.56	1.12
Total Assets	135.18	147.14	61.08	7.4
Accounts Payable	7.15	6.11	0.82	0.26
Current Debt	0.16	0.16	0.14	0.14
Other Current Liabilities	14.66	10.04	2.46	0.83
Total Current Liabilities	21.97	16.32	3.42	1.22
Long-Term Debt	0.11	0.25	0.31	3.18
Other Long-Term Liabilities	0.07	0.07	0.07	0.1
Total Long-Term Liabilities	0.18	0.32	0.38	3.27
Total Liabilities	22.14	16.64	3.8	4.5
Total Debt	0.28	0.41	0.45	3.31
Debt Growth	-32.77%	-9.05%	-86.32%	-
Common Stock	278.89	220.56	1.15	0.24
Retained Earnings	-165.69	-89.96	-38.57	-17.49
Comprehensive Income	-0.17	-0.09	0	0
Shareholders' Equity	113.04	130.5	-37.42	-17.25
Net Cash / Debt	130.18	139.81	58.41	2.48
Net Cash / Debt Growth	-6.89%	139.35%	2253.34%	-
Net Cash Per Share	4.65	7.20	17.43	1.03
Working Capital	111.66	129.83	56.11	5.05
Book Value Per Share	4.04	6.72	-11.16	-7.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).